102 related articles for article (PubMed ID: 16525901)
1. [The intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America].
Brunner E; Gargoloff P; Caro O; González C; Landa E; González CH; Barahona A; Soria D; Tamayo J; Rovner J; Adrianzen C; Silva H; Hodge A; O'Halloran R; Assunção SS;
Actas Esp Psiquiatr; 2006; 34(1):16-27. PubMed ID: 16525901
[TBL] [Abstract][Full Text] [Related]
2. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
4. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
5. Overview of the findings from the European SOHO study.
Suarez D; Haro JM
Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
[TBL] [Abstract][Full Text] [Related]
6. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
Novick D; Haro JM; Bertsch J; Haddad PM
J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
[TBL] [Abstract][Full Text] [Related]
7. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
Haro JM; Salvador-Carulla L
CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
[TBL] [Abstract][Full Text] [Related]
8. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study.
Novick D; Bousono M; Suarez D; Olivares JM; Montejo AL; Haro JM; Edgell ET; Ratcliffe M;
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):972-82. PubMed ID: 16023776
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Bitter I; Treuer T; Dyachkova Y; Martenyi F; McBride M; Ungvari GS
Eur Neuropsychopharmacol; 2008 Mar; 18(3):170-80. PubMed ID: 17884390
[TBL] [Abstract][Full Text] [Related]
10. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
13. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO).
Treuer T; Anders M; Bitter I; Dobre G; Pecenak J; Dyachkova Y; Harrison G; O'Mahoney J
Int J Psychiatry Clin Pract; 2006; 10(2):78-90. PubMed ID: 24940957
[TBL] [Abstract][Full Text] [Related]
15. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
16. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Lee P; Eung Kim C; Yoon Kim C; Lin WW; Habil H; Dyachkova Y; Mcbride M; Dossenbach M
Int J Psychiatry Clin Pract; 2008; 12(3):215-27. PubMed ID: 24931661
[TBL] [Abstract][Full Text] [Related]
17. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.
Olivares JM; Peuskens J; Pecenak J; Resseler S; Jacobs A; Akhras KS;
Curr Med Res Opin; 2009 Sep; 25(9):2197-206. PubMed ID: 19604073
[TBL] [Abstract][Full Text] [Related]
18. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
[TBL] [Abstract][Full Text] [Related]
19. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
